Clinical Trial Update: Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management [Phase 4]

View source ↗

Summary

This document describes a Phase 4 clinical trial evaluating the combination of abemaciclib with endocrine therapy for hormone receptor-positive, HER2-negative b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Metastatic Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Endocrine therapy (class) (endocrine therapy)

Snippet

Sponsor: Prof. Wolfgang Janni | Conditions: Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer | Phase 4 | Status: RECRUITING